Skip to main content
Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-Clinical Studies - HospiMedica 01-Aug-2020
Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-Clinical Studies - HospiMedica
Johnson & Johnson’s (New Brunswick, NJ, USA) lead vaccine candidate has successfully protected monkeys against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.
More...